Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease DOI Creative Commons
Thaninee Prasoppokakorn,

Varisa Limpijankit,

Siravich Seesodsai

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 76(12), P. 797 - 809

Published: Dec. 1, 2024

Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people living with HIV (PLWH) due to comorbidities and factors related infection. This study aimed identify clinical predictors of significant fibrosis PLWH MASLD. Materials Methods: A retrospective cohort was conducted having CD4 counts ≥200, enrolled between April October 2023 at two tertiary hospitals. The primary outcome identifying the (F≥2) defined by TE≥8 kPa. Secondary outcomes included MASLD prevalenceand characteristics. Results: Among 96 PLWH, 52 (54.2%) had mean age 49.7±8.0 years, 63.5% were male, BMI 25.8±4.1 kg/m². Obesity, diabetes, dyslipidemia present in 17.3%, 19.2%, 46.2% participants, respectively. CAP TE 285±36 dB/m 8.7±7.8 kPa, Significantfibrosis 24 patients (46.2%). Fibrosis scoring systems (FIB-4, APRI, NFS) demonstrated good accuracy (AUROCs: 0.84, 0.85, 0.76, respectively). Multivariate analysis identified fibrosis: higher (aOR 1.24, p=0.042), 3.96, p=0.038), AST 1.19, p=0.011). AGA pathway using steps (FIB-4 TE) improved reclassification risk, reducing number individuals indeterminate 12 out first step 7 second step. Conclusion: about half experiencing fibrosis. Predictors include dyslipidemia, BMI, elevated levels. accurately predict

Language: Английский

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study DOI Creative Commons
Seogsong Jeong, Yun Hwan Oh, Joseph Ahn

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(3), P. 487 - 499

Published: May 7, 2024

Background/Aims: To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and risk of hepatocellular carcinoma (HCC) a nationwide population-based cohort.Methods: Information on study participants was derived from Korea National Health Insurance Service database. The population consisted 5,080,410 who underwent two consecutive biennial health screenings 2009 2012. All were followed up until HCC, death, or 31 December 2020. MASLD status, as assessed by fatty index cardiometabolic factors, including persistent non-MASLD, resolved MASLD, incident with HCC evaluated using multivariable-adjusted Cox proportional hazards regression.Results: Among 39,910,331 person-years follow-up, 4,801 developed HCC. incidence resolved, incident, approximately 2.2-, 2.3-, 4.7-fold higher, respectively, than that those non-MASLD among Korean adult population. When stratifying according to change (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), (aHR, 1.85; CI, 1.63–2.10; 1.33; 1.18–1.50; P<0.001) had an increased compared non-MASLD.Conclusions: associated differential independent factors concomitant medications, providing additional information stratification patients MASLD.

Language: Английский

Citations

10
Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study DOI
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn

et al.

The American Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: June 27, 2024

INTRODUCTION: New terminologies of metabolic dysfunction-associated steatotic liver disease (MASLD) have been developed. We assessed hepatocellular carcinoma (HCC) risk across MASLD and/or alcohol intake. METHODS: included participants aged 40–79 years receiving a national health checkup from 2009 to 2010 in the Republic Korea, classified as follows: non-MASLD, MASLD, with increased intake (MetALD; weekly 210–420 g for male and 140–350 female individuals), alcohol-associated (ALD; excessive ≥420 or ≥350 individuals). The primary outcome was HCC incidence. estimated using multivariable Cox proportional hazard models. RESULTS: Among 6,412,209 participants, proportions MetALD, ALD cases were 59.5%, 32.4%, 4.8%, 3.4%, respectively. During follow-up (median 13.3 years), 27,118 had newly developed HCC. Compared (adjusted ratio [aHR] 1.66, 95% confidence interval [CI] 1.62–1.71) MetALD (aHR 2.17, CI 2.08–2.27) 2.34, 2.24–2.45) stepwise manner. Furthermore, older non-cirrhosis subgroups more vulnerable detrimental effects intake, concerning risk. older, female, cirrhosis subgroups, poses similar risks ALD. DISCUSSION: manner, compared non-MASLD. For an effective prevention HCC, comprehensive approach should be required modify both dysfunction habit.

Language: Английский

Citations

10
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality DOI Creative Commons
Hector Leal-Lassalle,

Olga Estévez-Vázquez,

Francisco Javier Cubero

et al.

npj gut and liver., Journal Year: 2025, Volume and Issue: 2(1)

Published: Jan. 10, 2025

MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.

Language: Английский

Citations

1
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance DOI Creative Commons
Angelo Armandi, Chiara Rosso, Gian Paolo Caviglia

et al.

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156080 - 156080

Published: Nov. 1, 2024

Language: Английский

Citations

6
Reply to “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma” DOI Creative Commons
Seogsong Jeong, Won Kim, Sang Min Park

et al.

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: 31(2), P. e208 - e209

Published: Jan. 7, 2025

Language: Английский

Citations

0
Reply to “MAFLD or MASLD: Which Better Represents the Prognosis of the Steatotic Liver Population” DOI Creative Commons
Seogsong Jeong, Won Kim, Sang Min Park

et al.

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: 31(2), P. e210 - e211

Published: Jan. 7, 2025

Language: Английский

Citations

0
Clinical Outcomes in Biopsy-Confirmed Steatotic Liver Disease: A Multicenter Prospective Cohort Study DOI
Gi‐Ae Kim,

Heejoon Jang,

Moon Young Kim

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Deep Learning-Based Prediction Models for Liver-Related and Cardiovascular Events in Steatotic Liver Disease DOI

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease DOI
Seogsong Jeong

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Preclinical Research on Cinnamic Acid Derivatives for the Prevention of Liver Damage: Promising Therapies for Liver Diseases DOI Creative Commons
Liseth Rubí Aldaba-Muruato,

Brayan Escalante-Hipólito,

Aldo Yoshio Alarcón-López

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(5), P. 1094 - 1094

Published: April 30, 2025

Background: Liver diseases are a global health issue with an annual mortality of 80,000 patients, mainly due to complications that arise during disease progression, as effective treatments lacking. Objectives: This study evaluated the hepatoprotective effects two derivatives cinnamic acid, LQM717 and LQM755, in murine model acute liver damage induced by carbon tetrachloride (CCl4, 4 g/kg, single dose p.o.). Methods: Male Wistar rats were pretreated five doses (20 mg/kg i.p.) or LQM755 (equimolar dose), starting 2 days before inducing hepatotoxic CCl4. Results: The key parameters hepatocellular function showed significant increases ALT, ALP, GGT, total direct bilirubin intoxicated CCl4, decreased glycogen serum albumin. Macroscopic microscopic examinations revealed reduced inflammation, necrosis, steatosis animals LQM755. Hepatomegaly was observed only + CCl4 group. statistically provided partial protection against ALT ALP completely prevented elevations GGT bilirubin. albumin reduction, while partially it. Both compounds depletion. Bioinformatic analysis identified 32 potential protein targets for 36 Conclusions: These findings suggest have CCl4-induced injury, providing information future studies other chronic models, well elucidate their mechanisms action.

Language: Английский

Citations

0